Lyell Immunopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Lyell Immunopharma, Inc. (LYEL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $17.67 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $18.55, a 126.50% increase year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $8.19, a 550.00% increase year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $1.26, a 24.10% decline year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $1.66, a 61.84% decline year-over-year.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $10.31, a 60.35% decline from fiscal 2024.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $26.00, a 23.08% decline from fiscal 2023.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $33.80, a 838.89% increase from fiscal 2022.
- Lyell Immunopharma, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $3.60, a 45.37% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $17.67 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $18.55 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | $10.31 10-K · filed 2026-03-12 | ||||
| 2025-06-30 | $8.93 10-Q · filed 2026-08-06 | ||||
| 2025-03-31 | $8.19 10-Q · filed 2026-05-06 | ||||
| 2024-12-31 | $26.00 10-K · filed 2026-03-12 | $1.30 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $1.35 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $1.35 10-Q · filed 2024-08-07 | ||||
| 2024-03-31 | $1.26 10-Q · filed 2024-05-06 | ||||
| 2023-12-31 | $33.80 10-K · filed 2026-03-12 | $1.69 10-K · filed 2024-02-28 | |||
| 2023-09-30 | $1.69 10-Q · filed 2024-11-07 | ||||
| 2023-06-30 | $1.72 10-Q · filed 2024-08-07 | ||||
| 2023-03-31 | $1.66 10-Q · filed 2024-05-06 | ||||
| 2022-12-31 | $3.60 10-K · filed 2025-03-11 | ||||
| 2022-09-30 | $4.33 10-Q · filed 2023-11-07 | ||||
| 2022-06-30 | $4.27 10-Q · filed 2023-08-08 | ||||
| 2022-03-31 | $4.35 10-Q · filed 2023-05-04 | ||||
| 2021-12-31 | $6.59 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | $6.55 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | $5.79 10-Q · filed 2022-08-04 | ||||
| 2021-03-31 | $4.29 10-Q · filed 2022-05-10 | ||||
| 2020-12-31 | $3.36 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $3.21 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $2.71 10-Q · filed 2021-08-12 | ||||
| 2019-12-31 | $2.24 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |